Methemoglobinemia induced by rasburicase in a pediatric patient: A case report and literature review
Authors:
- 21 December 2011
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 18 (4) , 425-431
Abstract
Rasburicase is a recombinant urate oxidase enzyme indicated for tumor lysis syndrome (TLS), a potential life-threatening oncologic emergency that occurs most commonly during chemotherapy for hematological malignancies. As a result of the defects in the physiological antioxidant pathway, erythrocytes of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are not protected against the oxidating stress exerted by hydrogen peroxide generated with the administration of rasburicase. Therefore, rasburicase is contraindicated in patients with known G6PD deficiency and the manufacturer recommends screening all patients with high risk for G6PD deficiency before initiating rasburicase therapy. However, it is logistically difficult in clinical settings because of the high risk of morbidity and mortality associated with TLS if treatment is delayed and the long turnaround time of the G6PD deficiency screening. Therefore, administering rasburicase to patients developing TLS before confirming a patient’s G6PD status is practically inevitable. Methemoglobinemia, and/or hemolysis, may result from the oxidative stress. Descriptions of the clinical course should it happen are limited in the literature. There are eight reported cases of rasburicase-related methemoglobinemia, with or without hemolytic anemia, in the literature of which five are pediatric patients. Six reports (including three pediatric patients) had detailed descriptions of the event and management. The recent reports of methemoglobinemia observed in patients with probable G6PD activity further complicated the picture. We are reporting a 16-year-old patient diagnosed with Burkitt’s lymphoma who developed methemoglobinemia after receiving one dose of rasburicase. He was managed by transfusion and oxygen support. The patient recovered well and the observed methemoglobinemia was reversible.Keywords
This publication has 21 references indexed in Scilit:
- Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemiaInternational Journal of Clinical Pharmacy, 2011
- Exchange transfusion as treatment for rasburicase induced methemoglobinemia in a glucose‐6‐phosphate dehydrogenase deficient patientPediatric Blood & Cancer, 2008
- Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based ReviewJournal of Clinical Oncology, 2008
- Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemiaPediatric Blood & Cancer, 2007
- Report of two cases of rasburicase-induced methemoglobinemiaLeukemia & Lymphoma, 2006
- Hemolysis and Methemoglobinemia Secondary to Rasburicase AdministrationAnnals of Pharmacotherapy, 2005
- Le déficit en glucose-6 phosphate déshydrogénase : protection contre le paludisme et risque d'accidents hémolytiquesComptes Rendus. Biologies, 2004
- Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancerCancer, 2003
- Inhibition of urate production by allopurinolBiochemical Pharmacology, 1977
- Prevention of Hyperuricemia in Leukemia and LymphomaJAMA, 1965